Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,407 across all filing types
Latest filing 2025-12-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory announcement from AstraZeneca PLC regarding 'Voting rights and capital' in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. It provides the total number of voting rights and issued share capital. While it relates to capital structure, it is a standard regulatory notification of voting rights rather than a specific financing update or share issue announcement. As it is a standard regulatory disclosure filed via RNS, it fits best under the RNS category.
2025-12-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal notification regarding the total number of voting rights and issued share capital of AstraZeneca PLC, issued in compliance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of regulatory disclosure regarding share capital and voting rights does not fit into specific categories like 'Share Issue' (which implies a change) or 'Major Shareholding' (which implies a specific investor's stake). As it is a standard regulatory disclosure required by the FCA, it falls under the 'Regulatory Filings' category.
2025-12-01 English
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER
Regulatory Filings
2025-11-26 English
Imfinzi approved in US for early gastric cancer
Regulatory Filings Classification · 100% confidence The document is a press release from AstraZeneca announcing the US FDA approval of 'Imfinzi' for the treatment of gastric and gastroesophageal cancers. It details the clinical trial results (MATTERHORN Phase III), provides quotes from company executives and medical professionals, and explains the regulatory context. This is a standard corporate announcement regarding product development and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it is a general regulatory/corporate announcement that does not fit into specific financial reporting categories like 10-K or IR.
2025-11-26 English
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND
Regulatory Filings
2025-11-24 English
AstraZeneca manufacturing investment in Maryland
Regulatory Filings Classification · 100% confidence The document is a press release issued via the Regulatory News Service (RNS) regarding a $2 billion capital investment in manufacturing facilities in Maryland. It details corporate strategy, expansion plans, and economic impact. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a general corporate announcement distributed via a regulatory channel, it is classified as a Regulatory Filing (RNS).
2025-11-24 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.